Mechanisms of P-gp inhibition and effects on membrane fluidity of a new rifampicin derivative, 1,8-dibenzoyl-rifampicin

Toxicology Letters

Volumn 220, Issue 3, 2013, Pages 259-266

  Vilas Boas, Vânia ^a   Silva, Renata ^a   Nunes, Cláudia ^a   Reis, Salette ^a   Ferreira, Luísa ^b   Vieira, Cátia ^b   Carvalho, Félix ^a   Bastos, Maria de Lourdes ^a   Remião, Fernando ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

1,8 Dibenzoyl rifampicin; Blood brain barrier; P glycoprotein inhibition; Passive diffusion; RBE4 cells; Rhodamine 123

Indexed keywords

1,8 DIBENZOYL RIFAMPICIN; ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; LIPOSOME; LUCIFERASE; LUCIFERIN; MULTIDRUG RESISTANCE PROTEIN; RHODAMINE 123; RIFAMPICIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANISOTROPY; ARTICLE; BLOOD BRAIN BARRIER; CELL LEVEL; CELL MEMBRANE; CELL MEMBRANE FLUIDITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EXPOSURE; DRUG SYNTHESIS; ENZYME ACTIVITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEADY STATE; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATASES; ADENOSINE TRIPHOSPHATE; ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; CELL LINE; CELL SURVIVAL; MEMBRANE FLUIDITY; P-GLYCOPROTEIN; RATS; RIFAMPIN;

EID: 84879514873     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2013.05.005     Document Type: Article

References (37)

1. Adams D.J., Knick V.C. P-glycoprotein mediated resistance to 5'-nor-anhydro-vinblastine (Navelbine). Investigational New Drugs 1995, 13:13-21.
2. Bachmeier C.J., Beaulieu-Abdelahad D., Ganey N.J., Mullan M.J., Levin G.M. Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine. Biopharmaceutics and Drug Disposition 2011, 32:233-244.
3. Coburger C., Lage H., Molnar J., Hilgeroth A. Impact of novel MDR modulators on human cancer cells: reversal activities and induction studies. Pharmaceutical Research 2009, 26:182-188.
4. Cordon-Cardo C., O'Brien J.P., Boccia J., Casals D., Bertino J.R., Melamed M.R. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. Journal of Histochemistry and Cytochemistry 1990, 38:1277-1287.
5. de Vries N.A., Buckle T., Zhao J., Beijnen J.H., Schellens J.H., van Tellingen O. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Investigational New Drugs 2012, 30:443-449.
6. DeLuca M., McElroy W.D. Kinetics of the firefly luciferase catalyzed reactions. Biochemistry 1974, 13:921-925.
7. Dinis-Oliveira R.J., Remiao F., Duarte J.A., Ferreira R., Sanchez Navarro A., Bastos M.L., Carvalho F. P-glycoprotein induction: an antidotal pathway for paraquat-induced lung toxicity. Free Radical Biology and Medicine 2006, 41:1213-1224.
8. Drori S., Eytan G.D., Assaraf Y.G. Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability. European Journal of Biochemistry 1995, 228:1020-1029.
9. Greiner B., Eichelbaum M., Fritz P., Kreichgauer H.P., von Richter O., Zundler J., Kroemer H.K. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. Journal of Clinical Investigation 1999, 104:147-153.
10. Hirayama C., Watanabe H., Nakashima R., Nanbu T., Hamada A., Kuniyasu A., Nakayama H., Kawaguchi T., Saito H. Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells. Pharmaceutical Research 2008, 25:827-835.
11. Kim R.B. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metabolism Reviews 2002, 34:47-54.
12. Kramer S.D., Hurley J.A., Abbott N.J., Begley D.J. Lipids in blood-brain barrier models in vitro. I: thin-layer chromatography and high-performance liquid chromatography for the analysis of lipid classes and long-chain polyunsaturated fatty acids. In Vitro Cellular and Developmental Biology: Animal 2002, 38:557-565.
13. Lakowicz J.R. Principles of Fluorescence Spectroscopy 2006, Springer, New York.
14. Lasic D.D. Liposomes: From Physics to Applications 1993, Elsevier.
15. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. The Journal of Biological Chemistry 1951, 193:265-275.
16. Lúcio M., Ferreira H., Lima J.L.F.C., Matos C., Castro B., Reis S. Influence of some anti-inflammatory drugs in membrane fluidity studied by fluorescence anisotropy measurements. Physical Chemistry and Chemical Physics 2004, 6:1493-1498.
17. Magnarin M., Morelli M., Rosati A., Bartoli F., Candussio L., Giraldi T., Decorti G. Induction of proteins involved in multidrug resistance (P-glycoprotein, MRP1, MRP2, LRP) and of CYP 3A4 by rifampicin in LLC-PK1 cells. European Journal of Pharmacology 2004, 483:19-28.
18. Miller T.P., Grogan T.M., Dalton W.S., Spier C.M., Scheper R.J., Salmon S.E. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. Journal of Clinical Oncology 1991, 9:17-24.
19. On N.H., Chen F., Hinton M., Miller D.W. Assessment of P-glycoprotein activity in the blood-brain barrier (BBB) using Near Infrared Fluorescence (NIRF) imaging techniques. Pharmaceutical Research 2011, 28:2505-2515.
20. Owen A., Goldring C., Morgan P., Park B.K., Pirmohamed M. Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements. British Journal of Clinical Pharmacology 2006, 62:237-242.
21. Palmeira A., Rodrigues F., Sousa E., Pinto M., Vasconcelos M.H., Fernandes M.X. New uses for old drugs: pharmacophore-based screening for the discovery of P-glycoprotein inhibitors. Chemical Biology and Drug Design 2011, 78:57-72.
22. Pontes H., Santos-Marques M.J., Fernandes E., Duarte J.A., Remiao F., Carvalho F., Bastos M.L. Effect of chronic ethanol exposure on the hepatotoxicity of ecstasy in mice: an ex vivo study. Toxicology In Vitro 2008, 22:910-920.
23. Prakash A.S. Selecting surfactants for the maximum inhibition of the activity of the multidrug resistance efflux pump transporter, P-glycoprotein: conceptual development. Journal of Excipients and Food Chemicals 2010, 1:51-59.
24. Roux F., Couraud P.O. Rat brain endothelial cell lines for the study of blood-brain barrier permeability and transport functions. Cellular and Molecular Neurobiology 2005, 25:41-58.
25. Roux F., Durieu-Trautmann O., Chaverot N., Claire M., Mailly P., Bourre J.M., Strosberg A.D., Couraud P.O. Regulation of gamma-glutamyl transpeptidase and alkaline phosphatase activities in immortalized rat brain microvessel endothelial cells. Journal of Cellular Physiology 1994, 159:101-113.
26. Santos L., Medeiros M.A., Santos S., Costa M.C., Tavares R., Curto M.J.M. NMR studies of some rifamycins. Journal of Molecular Structure 2001, 563-564:61-78.
27. Schinkel A.H., Wagenaar E., Mol C.A., van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. Journal of Clinical Investigation 1996, 97:2517-2524.
28. Shapiro A.B., Ling V. Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. Biochemical Pharmacology 1997, 53:587-596.
29. Silva R., Carmo H., Dinis-Oliveira R., Cordeiro-da-Silva A., Lima S.C., Carvalho F., Bastos Mde L., Remiao F. In vitro study of P-glycoprotein induction as an antidotal pathway to prevent cytotoxicity in Caco-2 cells. Archives of Toxicology 2011, 85:315-326.
30. Silva R., Carmo H., Vilas-Boas V., de Pinho P.G., Dinis-Oliveira R.J., Carvalho F., Silva I., Correia-de-Sa P., Bastos M.d.L., Remiao F. Doxorubicin decreases paraquat accumulation and toxicity in Caco-2 cells. Toxicology Letters 2013, 217:34-41.
31. Slater L.M., Sweet P., Stupecky M., Gupta S. Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. Journal of Clinical Investigation 1986, 77:1405-1408.
32. Staud F., Ceckova M., Micuda S., Pavek P. Expression and function of p-glycoprotein in normal tissues: effect on pharmacokinetics. Methods in Molecular Biology 2010, 596:199-222.
33. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Research 1981, 41:1967-1972.
34. Urbatsch I.L., Sankaran B., Weber J., Senior A.E. P-glycoprotein is stably inhibited by vanadate-induced trapping of nucleotide at a single catalytic site. The Journal of Biological Chemistry 1995, 270:19383-19390.
35. Varma M.V., Ashokraj Y., Dey C.S., Panchagnula R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacological Research 2003, 48:347-359.
36. Vilas-Boas V., Silva R., Gaio A.R., Martins A.M., Lima S.C., Cordeiro-da-Silva A., de Lourdes Bastos M., Remiao F. P-glycoprotein activity in human Caucasian male lymphocytes does not follow its increased expression during aging. Cytometry A 2011, 79:912-919.
37. Yang L., Fawcett J.P., Ostergaard J., Zhang H., Tucker I.G. Mechanistic studies of the effect of bile salts on rhodamine 123 uptake into RBE4 cells. Molecular Pharmaceutics 2011, 9:29-36.